CD4 and myeloid sarcoma: Immunologically, miR-223 has been confirmed to trigger the differentiation of CD4+ towards Th1 and Th17 cells, the leading cell type in MS pathology, and a defect of miR-223 results in resistance to EAE in mice [27].